Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Linong Ji

Showing results (361-370 of 588) with videos related to

Pageof 59
Sort By:
Eclinicalmedicine|August 25, 2021
IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b studyLinong Ji, Hongwei Jiang, Pei An, et al.
Diabetes, Obesity & Metabolism|August 19, 2024
The efficacy and safety of ISIS 449884 injection as monotherapy in patients with type 2 diabetes: A randomized phase II studyLinong Ji, Leili Gao, Zhikai Feng, et al.
Eclinicalmedicine|October 17, 2022
Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trialLinong Ji, Leili Gao, Hongwei Jiang, et al.
Frontiers in Endocrinology|January 25, 2021
Serum Ratio of Free Triiodothyronine to Thyroid-Stimulating Hormone: A Novel Index for Distinguishing Graves' Disease From Autoimmune ThyroiditisZhiyong Wu, Yu Zhu, Min Zhang, et al.
Plos One|August 15, 2014
Hyperglycemia and blood pressure treatment goal: a cross sectional survey of 18350 patients with type 2 diabetes in 77 tertiary hospitals in ChinaLinong Ji, Xinyue Zhi, Juming Lu, et al.
Diabetologia|June 26, 2014
Association of genetic predisposition to obesity with type 2 diabetes risk in Han Chinese individualsJingwen Zhu, Geng Zong, Ling Lu, et al.
Quantitative Imaging in Medicine and Surgery|May 14, 2023
Evaluation of activity of Graves' orbitopathy with multiparameter orbital magnetic resonance imaging (MRI)Jingyi Cheng, Xiuying Zhang, Jianxiu Lian, et al.
Diabetologia|July 10, 2024
Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trialLinong Ji, Rikke M Agesen, Stephen C Bain, et al.
Diabetes, Obesity & Metabolism|January 23, 2026
CGM-derived efficacy and overall safety of once-weekly insulin efsitora alfa (efsitora) relative to day of administration in adults with type 2 diabetesThomas Martens, Tadej Battelino, Simon Heller, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|July 21, 2021
Effect of Baseline Characteristics on Hypoglycaemia Risk with Insulin Glargine 100 U/mL: Post Hoc Analysis of the BEYOND 7 StudyHailong Wan, Binhong Wen, Xueying Wang, et al.
Pageof 59

Showing results (361-370 of 588) with videos related to

Sort By:
Pageof 59
Eclinicalmedicine|August 25, 2021
IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b studyLinong Ji, Hongwei Jiang, Pei An, et al.
Diabetes, Obesity & Metabolism|August 19, 2024
The efficacy and safety of ISIS 449884 injection as monotherapy in patients with type 2 diabetes: A randomized phase II studyLinong Ji, Leili Gao, Zhikai Feng, et al.
Eclinicalmedicine|October 17, 2022
Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trialLinong Ji, Leili Gao, Hongwei Jiang, et al.
Frontiers in Endocrinology|January 25, 2021
Serum Ratio of Free Triiodothyronine to Thyroid-Stimulating Hormone: A Novel Index for Distinguishing Graves' Disease From Autoimmune ThyroiditisZhiyong Wu, Yu Zhu, Min Zhang, et al.
Plos One|August 15, 2014
Hyperglycemia and blood pressure treatment goal: a cross sectional survey of 18350 patients with type 2 diabetes in 77 tertiary hospitals in ChinaLinong Ji, Xinyue Zhi, Juming Lu, et al.
Diabetologia|June 26, 2014
Association of genetic predisposition to obesity with type 2 diabetes risk in Han Chinese individualsJingwen Zhu, Geng Zong, Ling Lu, et al.
Quantitative Imaging in Medicine and Surgery|May 14, 2023
Evaluation of activity of Graves' orbitopathy with multiparameter orbital magnetic resonance imaging (MRI)Jingyi Cheng, Xiuying Zhang, Jianxiu Lian, et al.
Diabetologia|July 10, 2024
Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trialLinong Ji, Rikke M Agesen, Stephen C Bain, et al.
Diabetes, Obesity & Metabolism|January 23, 2026
CGM-derived efficacy and overall safety of once-weekly insulin efsitora alfa (efsitora) relative to day of administration in adults with type 2 diabetesThomas Martens, Tadej Battelino, Simon Heller, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|July 21, 2021
Effect of Baseline Characteristics on Hypoglycaemia Risk with Insulin Glargine 100 U/mL: Post Hoc Analysis of the BEYOND 7 StudyHailong Wan, Binhong Wen, Xueying Wang, et al.
Pageof 59